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Papillary Thyroid Microcarcinomas Are Different from Latent 
Papillary Thyroid Carcinomas at Autopsy
The aim of this study was to review the literature of latent papillary thyroid carcinomas 
(PTCs) discovered at autopsy and describe the available pathologic and demographic 
differences from a group of papillary thyroid microcarcinomas (PTMCs) the reported in a 
previous publication. We searched the PubMed for published articles describing latent 
thyroid carcinomas detected at autopsy. Meta-analysis was performed to identify 
differences between the clinicopathologic features of PTMCs analyzed previously in our 
institution (Group I) and those of latent PTCs described in autopsy studies (Group II). We 
identified 1,355 patients with PTMC (Group I) and 989 with latent PTCs (Group II). Mean 
patient age was 47.3 yr in Group I and 64.5 yr in Group II. The male:female ratio was 
1:10.9 in Group I and 1:1 in Group II. Most PTMCs (67.6%) were larger than 0.5 cm in 
size, whereas most latent PTCs were < 1-3 mm in diameter. The rates of multifocality were 
24.7% in Group I and 30.5% in Group II, and the rates of cervical lymph node metastasis 
were 33.4% in Group I and 10.0% in Group II. Currently available data indicated that 
clinically evident PTMCs differ from latent PTCs detected at autopsy. Therefore, these two 
entities should be regarded as different.
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INTRODUCTION
Latent carcinomas are carcinomas found in autopsy specimens, 
and latent thyroid carcinomas are defined as tumors 1.5 cm or 
less in diameter and not suspected clinically (1). Although no 
autopsy studies of the Korean population have been published, 
a PubMed search of autopsy reports from the 1960s onwards 
revealed that small foci of thyroid carcinoma were often present 
in the thyroid glands of individuals who died of unrelated illness 
(2). However, few comparative studies have been performed, 
because of differences in definitions, the pathological section-
ing techniques used, and the pathological criteria used to diag-
nose thyroid cancer (2).
 The prevalence of latent thyroid carcinomas, which are fre-
quently minute and occult, has been reported to range from 
1.0% to 35.6% in different systematic autopsy series, this inci-
dence is much higher than that of clinically evident carcinomas 
of the thyroid (1, 3-16). Papillary thyroid carcinoma (PTC) is a 
common thyroid malignancy, accounting for 86%-90% of thy-
roid cancer, and has indolent clinical characteristics. Papillary 
thyroid microcarcinomas (PTMCs), defined by the World Health 
Organization (WHO) as papillary thyroid carcinomas of maxi-
mum diameter of ≤ 1.0 cm (17), account for 30%-40% of PTCs, 
although recently their incidence is increasing rapidly (18). Most 
PTMCs are found incidentally, with some changing in clinical 
behavior to become clinical cancers (19). 
 At present, the relationship between latent PTCs and PTMCs 
is unclear, as in the treatment of patients with latent PTCs. There 
are two important questions with regard to latent PTCs. First, 
what is the relationship between latent papillary thyroid carci-
nomas and PTMC? Second, what should the therapeutic atti-
tude be toward a patient in whom PTMC is discovered?
 Because of the indolent behavior of PTMCs and the good 
prognosis of patients with these tumors, treatment of PTMCs is 
sometimes confused with that for latent PTCs. However, there 
is no evidence of similarity between PTMCs and latent PTCs. 
Despite this, autopsy studies have had a negative influence on 
the choice of therapy in patients with PTMC (20).
 This study aimed to review the literature of latent PTCs dis-
covered at autopsy and describe the available pathologic and 
demographic differences from a group of PTMCs the reported 
in a previous publication. 
MATERIALS AND METHODS
Study subjects 
The clinicopathologic features of PTMCs have been described 
previously in the Korean Journal of Head & Neck Oncology in 
2008 (18). Between January 2000 and December 2005, 1,355 
patients with PTMC treated at the Thyroid Cancer Center, Yon-
ORIGINAL ARTICLE
Oncology & Hematology
Lee YS, et al. • Papillary Thyroid Microcarcinomas and Latent Papillary Thyroid Carcinomas
http://jkms.org  677http://dx.doi.org/10.3346/jkms.2014.29.5.676
sei University College of Medicine, Seoul, Korea were evaluated 
(Group I).
 To identify patients with latent PTCs, the MEDLINE database 
was searched via the PubMed (http://www.ncbi.nih.gov/sites/
entrez/) on 24 February 2011 for the MeSH headings “occult”, 
“latent”, and “thyroid cancer”. We carefully reviewed all poten-
tially relevant articles, and studies were included in the analysis 
if they met all of the following criteria: 1) including papillary 
thyroid carcinoma, 2) performing autopsy, 3) providing avail-
able clinicopathologic characteristics, 4) where participants al-
ways included general population of both sexes without age re-
striction, and 5) written in English. 
 Of the identified articles, 15 were included in this study (Ta-
ble 1). These 15 papers described 8,619 autopsy specimens, 989 
of which (11.5%) had latent PTCs (1, 3-16).
 A meta-analysis was performed to identify differences be-
tween the clinicopathologic features of PTMCs evaluated in our 
institution (Group I) and those of latent PTCs evaluated in au-
topsy studies (Group II).
Statistical analysis
Categorical variables were summarized as counts and percent-
ages, and continuous variables as means. Comparisons between 
PTMCs and latent PTCs were performed using the one sample 
t-test, assuming a mean age of 47.3 in patients with PTMCs, 
whereas Pearson’s chi-square test was used to compare gender, 
tumor size (with cut-offs of 0.5 cm for PTMCs versus 1-3 mm 
cut-off value for latent PTCs), mutifocality, and cervical lymph 
node metastasis. All statistical analyses were performed using 
SAS 9.2 software (SAS Institute Inc., Cary, NC, USA). A P value 
less than 0.05 was considered statistically significant in all tests.
Ethics statement
This study was approved by the institutional review board of 
our institution, and was conducted according to the principles 
of the Helsinki declaration (IRB No. 3-2013-0209). 
RESULTS
This study included 1,355 cases of PTMC (Group I) and 989 cas-
es of latent PTCs from 15 autopsy reports (Group II). The clini-
copathologic results of PTMCs reported in the Korean Journal 
of Head & Neck Oncology are listed in Table 2. 
 We compared the following variables between two groups; 
patient age, sex distribution, multifocality, and cervical lymph 
node metastasis. These variables and results of statistical analy-
ses are listed in Table 3.
 Mean patient age was 47.3 yr in Group I and 65.4 yr in Group 
II (P = 0.003), and sex distribution (male:female) was 1:10.9 in 
Group I and 1:1 in Group II (P < 0.001) with statistical signifi-
cance.
 Tumor diameter was not comparable between the two groups: 
the majority (67.3%) of patients in Group I had tumors larger 
than 0.5 cm in diameter, and whereas tumors with tiny diame-
ters that were described as small foci (< 1-3 mm) were common 
in Group II.
 Multifocality was significantly less frequent in Group I than in 
Group II (24.7% vs 30.5%, P < 0.001). The rates of cervical lymph 
node metastasis rate were higher in Group I than in Group II (33.4% 
vs 10.0%) but the difference was not statistically significant.
Table 1. Studies on latent PTC at autopsy identified by a PubMed searching (1, 3-16)
Autopsy studies (n = 15) Country Section intervals Autopsy PTC %
Cancer 1975;36:1095-1099. Canada
Sendai, Japan
Poland
Columbia, USA
Japanese in Hawaii
2-3 mm 100
102
110
607
248
6
29
10
34
60
6.0
28.4
9.1
5.6
24.2
Cancer 1974;34:2072-2076. Minnesota, USA 2-3 mm 157 8 5.1
JAMA 1969;209:65-70. Hiroshima & Nagasaki, Japan 3-4 mm 3,067 536 17.5
Cancer 1979;43:1702-1706. Portugal    3 mm 600 39 6.5
Cancer 1981;47:319-323. Sweden 1-2 mm 500 32 6.3
Pathol Res Pract 1984;179:88-91. Chile 2-3 mm 274 8 2.9
Cancer 1985;56:531-538. Finland 2-3 mm 101 36 35.6
Cancer 1989;64:547-551. Argentina    2 mm 100 11 11.0
Cancer 1990;65:1173-1179. Tokushima, Japan *3 mm, 4 μm 408 46 11.3
Cancer 1989;64:1888-893. Brazil 3 mm 300 3 1.0
Cancer 1993;71:4022-4029. Spain 3 mm 725 51 7.0
Histopathology 1993;23:319-325. Minsk, Belarus 2-3 mm 215 19 8.8
Thyroid 2005;15:152-157. Hungary 1-2 mm 443 21 4.7
Endocrine Pathol 2001;12:23-31. Austria 3 mm 118 10 8.5
Pathology 1994;26:20-22. Singapore 1-2 mm 444 41 9.2
8,619 989 11.5
*Between 1981 and 1986, the thyroid glands of 366 cases were sectioned at 3 mm thickness, whereas between 1986 and 1987, the glands of 42 cases were sectioned at 4 
μm thickness. PTC, papillary thyroid carcinoma.
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Table 2. Clinicopathologic characteristics of patients with PTMCs (18)
Variables
Group M ( < 0.5 cm) Group T (0.5-1.0 cm) Total
P value
n = 439 (%) n = 916 (%) n = 1,355 (%)
Age (yr)
≥ 45
< 45
268 (61.0)
171 (39.0)
498 (54.4)
418 (45.6)
766 (56.5)
589 (43.5)
0.089
Gender
Male
Female
41 (9.1)
399 (90.9)
74 (8.1)
842 (91.9)
114 (8.4)
1,241 (91.6)
0.510
Incidental cancer detected by permanent pathology (occult carcinoma)
Yes
No
297 (67.8)
142 (32.2)
98 (10.7)
818 (89.3)
395 (29.2)
960 (70.8)
< 0.001
Extracapsular invasion
Yes
No
83 (18.9)
356 (81.1)
528 (57.6)
388 (42.4)
611 (45.1)
744 (54.9)
< 0.001
Invasion to adjacent structure
Yes
No
1 (0.2)
438 (99.8)
17 (1.9)
899 (98.1)
18 (1.3)
1,337 (98.7)
< 0.001
Multifocality
Yes
No
64 (14.6)
375 (82.0)
271 (29.6)
645 (70.4)
335 (24.7)
1,020 (75.3)
< 0.001
Central neck node metastasis
Yes
No
79 (18.0)
360 (82.0)
374 (40.8)
542 (59.2)
453 (33.4)
902 (66.6)
< 0.001
Lateral neck node metastasis
Yes
No
1 (0.2)
438 (99.8)
76 (8.3)
840 (91.7)
77 (5.7)
1,278 (94.3)
< 0.001
Distant metastasis at presentation
Yes
No
0 (0.0)
439 (100.0)
3 (0.3)
913 (99.7)
3 (0.2)
1,352 (99.8)
0.231
Local recurrence
Yes
No
2 (0.5)
437 (99.5)
11 (1.2)
905 (98.8)
13 (1.0)
1,342 (99.0)
0.420
Group M, minute carcinoma ( < 0.5 cm); Group T, tiny carcinoma (0.5-1.0 cm).
Table 3. Comparison of patients with PTMCs and latent PTCs at autopsy
Variables
Group I
Microcarcinomas
Group II
Latent carcinomas P value
n = 1,355 n = 989
Age 47.3 64.5     0.003
Gender ratio  
   (male:female)
1:10.9 1:1 < 0.001
Tumor size > 0.5 cm (67.3 %) Small foci ( < 1-3 mm) NA
Multifocality 24.7 % 30. 5% < 0.001
Cervical lymph node  
   metastasis
33.4 % 10.0 % NA
NA, not available.
DISCUSSION
Of the 8,619 thyroid glands obtained in 15 autopsy studies, 989 
(11.5%) were positive for latent PTC (Table 1). However, the prev-
alence of latent PTC has been found to vary considerably, from 
1.0% to 35.6%. Comparing this prevalence among autopsy stud-
ies is complicated by differences in methods of examination, 
section intervals (ranging from 4 μm to 4 mm), diagnostic crite-
ria, and sample selection. In particular, different methods of ex-
amination can have a profound effect on the observed preva-
lence of carcinoma (1). 
 One factor that may cause a spurious increase in the rate of 
latent PTC at autopsy is bias of the entire series in favor of thy-
roid carcinoma or a related disease (1). We, however, did not 
directly select for PTC at autopsy, because almost all of the la-
tent carcinomas were small and clinically occult. There also was 
no evidence of indirect selection for patients with thyroid carci-
noma. Another factor related to an increased prevalence rate is 
that the incidence of thyroid carcinoma is fundamentally very 
high. 
 This can be explained by the two-stage theory. A thyroid car-
cinoma may arise in response to various factors, including en-
vironmental and genetic factors, but its growth may be deficient 
and it may lack clinical characteristics. Subsequently, other fac-
tors may promote the development of clinical thyroid carcinoma 
(21, 22). This two-stage theory explains the small size, describ-
ed as foci, and the sclerotic characteristics of the latent PTCs. 
 The latent PTC group contained a high proportion of very 
small tumors. Most (67.3%) patients with PTMC had tumors 
larger than 0.5 cm in diameter, whereas most latent PTCs were 
small foci (< 1-3 mm in size). Moreover, most of the latent PTCs 
showed sclerotic patterns, indicating that these tumors had aris-
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en a long time prior to autopsy. 
 Papillary carcinomas arise as non-sclerosing tumors; during 
further growth, stromal fibrosis (non-encapsulated sclerosing 
tumors) occurs or a fibrous capsule (encapsulated tumors) forms 
with various degrees of cellular infiltration, with the latter likely 
associated with a host reaction (10).
 In contrast to the marked female predominance of clinical 
thyroid carcinoma, the prevalence of latent carcinomas did not 
differ significantly between men and women. Also, whereas 
most hospital-based series have found a slight male predomi-
nance, we observed a 1:1 ratio of latent PTCs in males and fe-
males. Moreover, patients with latent PTC were older than those 
with PTMC. Older age and male predominance, however, may 
be caused by a selection bias in patients with latent PTCs, since 
these studies were based on autopsy data.
 Multifocality was significantly more prevalent in patients with 
latent PTC than in those with PTMC (30.5% vs 24.7%, P < 0.001). 
In contrast, cervical lymph node metastasis was more prevalent 
in patients with PTMC than in those with latent PTC (33.4% vs 
10.0%), probably because lymph node status was not fully ex-
amined in autopsy studies.
 In conclusion, despite the limited ability to compare variables 
between patient with PTMC and those with latent PTC, and de-
spite selection bias, there are differences between these groups, 
indicating that latent PTCs and PTMCs should be considered 
distinct entities. The choice of therapy in patients with PTMC 
should not be influenced by the concept of latent PTCs. Future 
autopsy studies should include molecular and metabolic markers. 
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